Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grace Mwangoka

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Scientific Reports|May 22, 2024
Pilot deployment of a community health care worker in distributing and offering the COVID-19 AgRDT in TanzaniaMwifadhi Mrisho, Grace Mwangoka, Ali M Ali, et al.
Scientific Reports|July 25, 2020
Molecular malaria surveillance using a novel protocol for extraction and analysis of nucleic acids retained on used rapid diagnostic testsEtienne A Guirou, Tobias Schindler, Salome Hosch, et al.
BMC Infectious Diseases|July 10, 2026
Human exposure to Crimean-Congo hemorrhagic fever virus is associated with livestock management and handling practices in southcentral Tanzania, 2023-2024Cheryl Meehan, Grace Mwangoka, Mwokozi Mwanzalilla, et al.
Journal of Clinical Microbiology|April 18, 2014
A quality control program within a clinical trial Consortium for PCR protocols to detect Plasmodium speciesSteve M Taylor, Alfredo Mayor, Ghyslain Mombo-Ngoma, et al.
The Journal of Infectious Diseases|August 26, 2010
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunizationSelidji T Agnandji, Kwaku Poku Asante, John Lyimo, et al.
The Lancet. Infectious Diseases|July 26, 2011
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trialKwaku Poku Asante, Salim Abdulla, Selidji Agnandji, et al.
Vaccine|March 18, 2025
Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024Radhika Gharpure, Carolin Vegvari, Alemseged Abdissa, et al.
The New England Journal of Medicine|October 20, 2011
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children, Selidji Todagbe Agnandji, Bertrand Lell, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Scientific Reports|May 22, 2024
Pilot deployment of a community health care worker in distributing and offering the COVID-19 AgRDT in TanzaniaMwifadhi Mrisho, Grace Mwangoka, Ali M Ali, et al.
Scientific Reports|July 25, 2020
Molecular malaria surveillance using a novel protocol for extraction and analysis of nucleic acids retained on used rapid diagnostic testsEtienne A Guirou, Tobias Schindler, Salome Hosch, et al.
BMC Infectious Diseases|July 10, 2026
Human exposure to Crimean-Congo hemorrhagic fever virus is associated with livestock management and handling practices in southcentral Tanzania, 2023-2024Cheryl Meehan, Grace Mwangoka, Mwokozi Mwanzalilla, et al.
Journal of Clinical Microbiology|April 18, 2014
A quality control program within a clinical trial Consortium for PCR protocols to detect Plasmodium speciesSteve M Taylor, Alfredo Mayor, Ghyslain Mombo-Ngoma, et al.
The Journal of Infectious Diseases|August 26, 2010
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunizationSelidji T Agnandji, Kwaku Poku Asante, John Lyimo, et al.
The Lancet. Infectious Diseases|July 26, 2011
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trialKwaku Poku Asante, Salim Abdulla, Selidji Agnandji, et al.
Vaccine|March 18, 2025
Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024Radhika Gharpure, Carolin Vegvari, Alemseged Abdissa, et al.
The New England Journal of Medicine|October 20, 2011
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children, Selidji Todagbe Agnandji, Bertrand Lell, et al.
Pageof 2